Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Breast Neoplasms 1

Interventions

pembrolizumab 61Cisplatin 37Carboplatin 23Radiotherapy 21Cetuximab 19Magnetic Resonance Spectroscopy 18Paclitaxel 17Specimen Handling 13Docetaxel 12Fluorouracil 11Nivolumab 10tislelizumab 9Surgical Procedures, Operative 8Radiotherapy, Intensity-Modulated 7Radiation 7cemiplimab 6Standard of Care 6Platinum 6Chemoradiotherapy 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6toripalimab 5Drug Therapy 5130-nm albumin-bound paclitaxel 5atezolizumab 4Taxes 4Ipilimumab 4Immunotherapy 4Fluorodeoxyglucose F18 4Cyclophosphamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Squamous Cell Carcinoma of Head and Neck × Interleukin-15 × Clear all
NCT06239220 2026-02-27

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
25 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡